EGFR and non-small cell lung carcinoma: Wu et al., in a meta-analysis, investigated the efficacy and safety of EGFR-TKI plus chemotherapy compared to EGFR-TKI alone as a first-line treatment in advanced NSCLC patients with the common EGFR mutation.